Bellerophon Therapeutics, Inc. (BLPH)

Bellerophon Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Selling, General & Admin	6.02	7.15	8.39	6.44	7.62	6.75	7.11	14.87	13.78	9.01	Upgrade
Research & Development	16.36	13.02	17.89	11.03	20.26	17.85	16.65	33.37	45.98	52.99	Upgrade
Other Operating Expenses	0	0	0	-0.67	27.88	24.6	23.76	48.24	0	0	Upgrade
Operating Expenses	22.38	20.16	26.28	17.47	27.88	24.6	23.76	46.57	59.75	62	Upgrade
Operating Income	-22.38	-20.16	-26.28	-17.47	-27.88	-24.6	-23.76	-46.57	-59.75	-62	Upgrade
Interest Income	0	0	0	0	0.38	0.18	0.1	0.11	0.08	0	Upgrade
Interest Expense	0.14	0.01	0.25	0	0	0	0	0	0	0	Upgrade
Other Expense / Income	-0.27	-0.61	0.33	-2.41	-24.88	0.56	0.59	-1.18	-	-	Upgrade
Pretax Income	-22.25	-19.56	-26.85	-15.07	-2.63	-54.82	-24.25	-46.46	-59.67	-62	Upgrade
Income Tax	-2.42	-1.8	-2.13	-1.8	-5.44	29.85	-0.44	1.18	0	0	Upgrade
Net Income	-19.83	-17.76	-24.73	-13.27	2.81	-54.82	-23.81	-46.46	-59.67	-62	Upgrade
Shares Outstanding (Basic)	10	10	8	5	4	3	1	1	12	13	Upgrade
Shares Outstanding (Diluted)	10	10	8	5	4	3	1	1	12	13	Upgrade
Shares Change	0.51%	21.88%	73.14%	3.85%	67.00%	158.68%	22.74%	-93.13%	-7.75%	-	Upgrade
EPS (Basic)	-2.08	-1.87	-3.17	-2.95	0.65	-21.11	-23.72	-56.81	-5.01	-4.80	Upgrade
EPS (Diluted)	-2.08	-1.87	-3.17	-2.95	0.65	-21.11	-23.72	-56.81	-5.01	-4.80	Upgrade
Free Cash Flow	-17.77	-22.82	-19.88	-12.94	-15.5	-15.74	-17.24	-46.72	-70.56	-57.96	Upgrade
Free Cash Flow Per Share	-1.86	-2.40	-2.55	-2.87	-3.57	-6.06	-17.17	-57.13	-5.93	-4.49	Upgrade
EBITDA	-22.39	-20.76	-26.13	-19.81	-52.4	5.8	-23.17	-46.57	-59.37	-61.57	Upgrade
Depreciation & Amortization	0.07	0.1	0.15	0.35	0.36	0.37	0.4	0.38	0.39	0.43	Upgrade
EBIT	-22.45	-20.86	-26.28	-20.16	-52.76	5.43	-23.57	-46.95	-59.75	-62	Upgrade

Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.